ArticleFrontiers in oncology2026
Phosphorylation of tumour suppressor Amotl2 by IKBKE kinase promotes YAP1 signalling, enhancing glioblastoma growth.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), a member of the serine/threonine kinase family, is an important oncogene in glioblastoma. IKBKE is involved in the progression of multiple tumours in glioblastoma (GBM), including tumour invasion, migration, and proliferation. Here, we report an IKBKE-angiomotin-like protein 2 (Amotl2)-yes-associated protein 1 (YAP1) axis in which IKBKE inhibits the protein expression of Amotl2, while Amotl2 regulates the nuclear transport of the YAP1 protein, which has been implicated in brain tumour development and progression. Data analysis of multiple IKBKE mRNA databases of glioma and immunohistochemical analysis of a tissue chip indicated that higher IKBKE expression was associated with higher malignancy and shorter survival in glioma patients. IKBKE downregulation significantly inhibited GBM cell proliferation and restrained tumour growth in a GBM mouse model. Moreover, IKBKE phosphorylates Amotl2, promoting Amotl2 ubiquitination and degradation, leading to YAP1 entry into the nucleus and the activation of downstream genes. In summary, our results are the first to show that IKBKE phosphorylates Amotl2 and that GBM cell proliferation is regulated by the IKBKE↑-Amotl2↓-YAP1↑ axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.